CJC-1295 with DAC Peptide: Long-Acting GHRH Analog | Research Grade

CJC-1295 with DAC: Long-Acting GHRH Analog for Research Use

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone, GHRH(1-29), with four amino acid substitutions for stability and a Drug Affinity Complex: a maleimidopropionic acid linker that reacts with cysteine-34 of circulating serum albumin. That covalent albumin bond is what separates it from every other GHRH analog: instead of minutes, the peptide circulates for days. In the published human trials the estimated half-life was 5.8 to 8.1 days, with IGF-1 elevation lasting up to 28 days after multiple doses. LiveWell supplies it as a 10 mg lyophilized vial strictly for in-vitro laboratory research use only.

Chemical Information

• Name: CJC-1295 with DAC (DAC:GRF)
• CAS Number: 863288-34-0
• Type: Synthetic tetrasubstituted GHRH(1-29) analog with Drug Affinity Complex (research grade)
• Length: 29 amino acids plus Lys-DAC linker
• Molecular weight: approximately 3647 g/mol
• Mechanism: GHRH receptor agonist on pituitary somatotrophs; covalent albumin binding via maleimidopropionic acid
• Half-life: 5.8 to 8.1 days reported in published human trials
• Vial size: 10 mg lyophilized powder
• Purity: ≥99% (HPLC, third-party tested)

Why Researchers Study CJC-1295 with DAC

1. Albumin-binding reference compound. CJC-1295 is the canonical example of the Drug Affinity Complex approach: a single covalent albumin bond converting a minutes-long GHRH signal into a week-long one. It is studied as a template for peptide half-life extension chemistry.

2. Sustained GH/IGF-1 axis research. The JCEM trials reported 2 to 10-fold GH elevation for at least 6 days and IGF-1 elevation of 1.5 to 3-fold lasting 9 to 11 days after a single dose, giving researchers a tool for sustained rather than pulsatile axis activation.

3. Preserved pulsatility. The Ionescu study showed GH secretion remained pulsatile during continuous CJC-1295 stimulation, a key finding for hypothalamic-pituitary feedback research, in contrast with continuous exogenous GH.

4. Comparative secretagogue research. CJC-1295 (GHRH receptor) is studied against GHS-R agonists such as Ipamorelin, Hexarelin and the GHRPs to separate the two receptor systems that drive GH release, and against Sermorelin and Tesamorelin inside the GHRH family.

Published Clinical Literature (Research Reference)

For context only. These are results from the original ConjuChem clinical program. These are results cited from peer-reviewed sources; they are not claims about LiveWell’s research-grade material.

• Phase 1 single and multiple dose (J Clin Endocrinol Metab, 2006): single subcutaneous doses raised mean GH 2 to 10-fold for at least 6 days and IGF-1 1.5 to 3-fold for 9 to 11 days; half-life estimated at 5.8 to 8.1 days; after multiple doses IGF-1 remained elevated up to 28 days.
• Pulsatility study (J Clin Endocrinol Metab, 2006): a single injection increased trough GH about 7.5-fold and IGF-1 45% while GH secretion stayed pulsatile during continuous stimulation.
• Serum proteomics (Growth Horm IGF Res, 2009): CJC-1295 activation of the GH/IGF-1 axis produced measurable serum protein profile changes in healthy adults.
• Anti-doping detection (Anal Bioanal Chem, 2016): immunoaffinity LC-HRMS/MS methods identify CJC-1295 in human plasma; the compound is on the WADA prohibited list (S2).
• Regulatory: never approved anywhere; ConjuChem development was halted; prohibited in sport by WADA.

Storage & Handling

• Store lyophilized vials refrigerated at 2 to 8°C, protected from light and heat
• Reconstitute with bacteriostatic water; reconstituted material has a shorter storage window
• Follow your laboratory’s standard peptide handling protocol

⚠️ Disclaimer: CJC-1295 with DAC research peptide is intended strictly for laboratory research and in-vitro use only. It is not a drug, food, cosmetic, or dietary supplement. This product has not been evaluated or approved by the FDA and is not for human or veterinary use. No therapeutic, weight-management or metabolic-health claims are made or implied.

Regulatory status: CJC-1295 is an investigational compound that was never approved in any country; its original clinical development program was discontinued. It is listed on the WADA prohibited list (section S2). The research-grade material sold by LiveWell is not a drug product: it is not manufactured, compounded, or approved for pharmaceutical use, and is strictly for in-vitro laboratory research. Nothing on this page constitutes medical advice.

CJC-1295 with DAC research reference: View the Phase 1 trial on PubMed

Pre-Order CJC-1295 with DAC Research Peptide: cGMP Manufactured in Dallas, TX

Qualified researchers can pre-order CJC-1295 with DAC directly from the manufacturer. LiveWell Peptides produces research-grade CJC-1295 with DAC in our cGMP facility in Dallas, Texas. Every vial is third-party tested to verify ≥99% HPLC purity, amino acid identity by mass spectrometry, and endotoxin limits by LAL testing, and the batch COA is published on our COA page on the day of release. Pre-orders ship in the order received (expected ship date: to be announced); once released, US orders placed before 2pm CT (Mon to Fri) ship same-day in cold-chain packaging, with free domestic shipping over $200. International shipping is available.

Why Researchers Source CJC-1295 with DAC from LiveWell

Documentation, not claims. Every batch ships with a verified COA confirming identity and purity, published on our COA page rather than supplied only on request.

Four-point analytical testing. HPLC for purity, mass spectrometry for amino acid identity, and LAL testing for endotoxins, with independent third-party verification on top of in-house quality control.

US manufacturing and cold-chain logistics. Orders ship from our Dallas, Texas facility, with international shipping to Colombia, Mexico, Brazil, Argentina, Chile and Peru.

Related research compounds

CJC-1295 (no DAC) + Ipamorelin blend · Sermorelin (GHRH 1-29) · Ipamorelin (GHS-R agonist) · Tesamorelin (stabilized GHRH) · Bacteriostatic Water · Certificates of Analysis

Research literature

Selected peer-reviewed sources for research reference:

• Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID: 16352683
• Ionescu M et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PMID: 17018654
• Sackmann-Sala L et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. PMID: 19386527
• Knoop A et al. (2016). Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. PMID: 26879649

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Frequently Asked Questions

Péptidos de investigación disponibles con envío internacional. CJC-1295 con DAC de grado de investigación fabricado en instalaciones cGMP en Dallas, Texas. Certificado de análisis incluido con cada lote. Solo para uso en investigación.

Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research. NOT for human or animal consumption. LiveWell Peptides makes no medical claims.